Search - tctmd.com

Displaying 41 - 60 of 69

Sort: Relevancy | Date

News Conference News ESC 2018

Redefined ‘High-Quality’ Diet Lowers Risk of All-Cause Mortality: PURE

Michael O'Riordan

August 28, 2018

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Todd Neale

August 26, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

Shelley Wood

August 29, 2017

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Presentation ESC 2017

Impact of BMI on Clinical Outcomes and Readmissions After Cardiac Catheterization

Presenter: Afnan Tariq

August 26, 2017

Advertisement

Redefined ‘High-Quality’ Diet Lowers Risk of All-Cause Mortality: PURE

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Impact of BMI on Clinical Outcomes and Readmissions After Cardiac Catheterization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content